Short Interest in IPSEN (OTCMKTS:IPSEY) Drops By 39.6%

IPSEN (OTCMKTS:IPSEY) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 297 shares, a decrease of 39.6% from the April 15th total of 492 shares. Based on an average daily volume of 680 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the stock are sold short.

IPSEN Stock Performance

Shares of IPSEY remained flat at $48.76 during trading hours on Monday. The stock had a trading volume of 109 shares, compared to its average volume of 868. IPSEN has a one year low of $28.59 and a one year high of $51.10. The stock has a 50 day moving average price of $47.22 and a 200-day moving average price of $41.60.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Thursday. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN presently has an average rating of “Hold”.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).